MA45901A - Procã‰dã‰s et intermã‰diaires pour la prã‰paration de {1-(ã‰thylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azã‰tidin-3-yl}acã‰tonitrile - Google Patents

Procã‰dã‰s et intermã‰diaires pour la prã‰paration de {1-(ã‰thylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azã‰tidin-3-yl}acã‰tonitrile

Info

Publication number
MA45901A
MA45901A MA045901A MA45901A MA45901A MA 45901 A MA45901 A MA 45901A MA 045901 A MA045901 A MA 045901A MA 45901 A MA45901 A MA 45901A MA 45901 A MA45901 A MA 45901A
Authority
MA
Morocco
Prior art keywords
azã
acã
thylsulfonyl
tidin
tonitrile
Prior art date
Application number
MA045901A
Other languages
English (en)
Inventor
Michael Edward Kobierski
Michael E Kopach
Joseph R Martinelli
David Lee Varie
Thomas Michael Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56204068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA45901(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA45901A publication Critical patent/MA45901A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA045901A 2015-06-19 2016-06-16 Procã‰dã‰s et intermã‰diaires pour la prã‰paration de {1-(ã‰thylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azã‰tidin-3-yl}acã‰tonitrile MA45901A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562182040P 2015-06-19 2015-06-19

Publications (1)

Publication Number Publication Date
MA45901A true MA45901A (fr) 2019-06-19

Family

ID=56204068

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045901A MA45901A (fr) 2015-06-19 2016-06-16 Procã‰dã‰s et intermã‰diaires pour la prã‰paration de {1-(ã‰thylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azã‰tidin-3-yl}acã‰tonitrile

Country Status (26)

Country Link
US (2) US20180134713A1 (fr)
EP (1) EP3310781A1 (fr)
JP (1) JP2018519280A (fr)
KR (1) KR20180008637A (fr)
CN (1) CN107660206A (fr)
AR (1) AR104918A1 (fr)
AU (1) AU2016280815A1 (fr)
BR (1) BR112017024613A2 (fr)
CA (1) CA2984627A1 (fr)
CL (1) CL2017003112A1 (fr)
CO (1) CO2017013226A2 (fr)
CR (1) CR20170533A (fr)
DO (1) DOP2017000300A (fr)
EA (1) EA201792308A1 (fr)
EC (1) ECSP17083426A (fr)
HK (1) HK1248699A1 (fr)
IL (1) IL255386A0 (fr)
MA (1) MA45901A (fr)
MX (1) MX2017015837A (fr)
NZ (1) NZ736999A (fr)
PE (1) PE20180504A1 (fr)
PH (1) PH12017502360A1 (fr)
SV (1) SV2017005586A (fr)
TN (1) TN2017000530A1 (fr)
TW (1) TWI622591B (fr)
WO (1) WO2016205487A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108341818A (zh) * 2017-01-21 2018-07-31 南京华威医药科技开发有限公司 巴瑞克替尼及其磷酸盐的新晶型及其制备方法
CA3055233C (fr) 2017-01-23 2022-08-09 Shanghai Longwood Biopharmaceuticals Co., Ltd. Inhibiteur de kinase jak, son procede de preparation et son utilisation
CN106946917B (zh) * 2017-03-20 2019-06-11 杭州科巢生物科技有限公司 一种jak抑制剂巴瑞替尼及其中间体的新合成方法
CN107739328B (zh) * 2017-11-22 2020-03-20 海化生命(厦门)科技有限公司 用于合成巴瑞替尼的关键中间体1的制备方法
CN108129482A (zh) * 2017-12-13 2018-06-08 江苏中邦制药有限公司 一种巴瑞替尼的制备方法
US10766900B2 (en) 2017-12-29 2020-09-08 Formosa Laboratories, Inc. Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
WO2020072870A1 (fr) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Formes co-cristallines du baricitinib
TW202033198A (zh) 2018-10-17 2020-09-16 美商美國禮來大藥廠 以巴瑞克替尼(baricitinib)治療原發性膽汁性膽管炎及原發性硬化性膽管炎
US11548895B2 (en) 2019-04-24 2023-01-10 Elanco Us Inc. Process for making crystalline 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile
US20250041304A1 (en) 2021-07-30 2025-02-06 Eli Lilly And Company Treatment of Hand Eczema with Baricitinib
CN117720543A (zh) * 2023-12-13 2024-03-19 东北林业大学 一种巴瑞替尼的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821374A (en) * 1995-11-21 1998-10-13 Hoffmann-La Roche Inc. Process for the oxidation of alcohols
HUE029767T2 (en) * 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
KR20130094710A (ko) * 2010-04-14 2013-08-26 어레이 바이오파마 인크. Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘
CN102557901B (zh) * 2010-12-15 2014-06-11 上海医药工业研究院 6-氯己醛的制备方法
RS62867B1 (sr) * 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
CN105541891B (zh) * 2016-02-04 2017-11-28 东南大学 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法

Also Published As

Publication number Publication date
IL255386A0 (en) 2017-12-31
CR20170533A (es) 2018-01-25
NZ736999A (en) 2019-05-31
BR112017024613A2 (pt) 2018-07-31
SV2017005586A (es) 2018-04-24
AR104918A1 (es) 2017-08-23
TN2017000530A1 (en) 2019-04-12
CL2017003112A1 (es) 2018-06-01
TWI622591B (zh) 2018-05-01
KR20180008637A (ko) 2018-01-24
MX2017015837A (es) 2018-04-10
JP2018519280A (ja) 2018-07-19
PE20180504A1 (es) 2018-03-09
WO2016205487A1 (fr) 2016-12-22
DOP2017000300A (es) 2018-01-31
AU2016280815A1 (en) 2017-11-23
US20190062337A1 (en) 2019-02-28
PH12017502360A1 (en) 2018-06-25
HK1248699A1 (zh) 2018-10-19
TW201712015A (zh) 2017-04-01
CO2017013226A2 (es) 2018-03-28
CN107660206A (zh) 2018-02-02
ECSP17083426A (es) 2018-02-28
US20180134713A1 (en) 2018-05-17
EP3310781A1 (fr) 2018-04-25
CA2984627A1 (fr) 2016-12-22
EA201792308A1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
MA45901A (fr) Procã‰dã‰s et intermã‰diaires pour la prã‰paration de {1-(ã‰thylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azã‰tidin-3-yl}acã‰tonitrile
CL2014003566A1 (es) Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson.
IL247901A0 (en) Additional salts of (s)-2-(1-(6-amino-5-cyanopyrimidine-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1 ,2,4]triazine-5-carbonitrile
EP3159340A4 (fr) Nouvel inhibiteur de la tyrosine kinase de bruton
EP3280633A4 (fr) Déambulateur roulant pliable
EP3181559B8 (fr) Dérivé 2-(aniline 2,4,5-substituée)pyrimidine, composition pharmaceutique et leur utilisation
SG10201911523YA (en) Inhibitors of bruton's tyrosine kinase
EA201691327A1 (ru) Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
EP3177366A4 (fr) Combinaisons d'inhibiteurs de tyrosine kinase de bruton et leurs utilisations
CL2016003145A1 (es) Compuestos de [1,2,4]triazol sustituido
DK3439662T3 (da) Væskeformige formuleringer af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
EP3299366A4 (fr) Composés de pyrazole substitués contenant de la pyrimidine et procédé de préparation et utilisation de ceux-ci
ZA201701131B (en) Novel 2,5-substituted pyrimidines as pde4 inhibitors
EP3411031A4 (fr) Compositions de dompéridone deutérée et méthodes pour la thérapie de troubles
EP3209641A4 (fr) Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de ror et pour le traitement de maladie
ZA201701814B (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
EP3102571A4 (fr) Pyrimidines substituées utiles en tant qu'inhibiteurs de kinase d'egfr-t790m
ZA201804843B (en) Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide
IL234966A0 (en) Crystal forms of (4-(s-amino-4)-1)-n-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo [3,2-d]pyrimidin-4-yl)piperidine-4-carboxamide
IL251249B (en) Process for the preparation of 1-(3,5-dichloro-4-fluoro-phenyl)-2,2,2-trifluoro-ethanone
EP3323828A4 (fr) Anticorps de détermination du sexe du sperme, et son utilisation
EP3312172A4 (fr) Dérivés d'aminopyrazole
FR3003460B1 (fr) Equipement pour la determination de l'œil directeur
EP3554499A4 (fr) Aminopyrazoles en tant qu'inhibiteurs de janus kinase
IL265634A (en) Novel 5-substituted imidazolylmethyl derivatives